Viewing Study NCT00001805

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2026-01-22 @ 3:27 PM
Study NCT ID: NCT00001805
Status: COMPLETED
Last Update Posted: 2008-03-04
First Post: 1999-11-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
None Colonic Neoplasms View
None Lung Neoplasms View
None Pancreatic Neoplasms View
None Stomach Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Colon Cancer View
None Gastric Cancer View
None Lung Cancer View
None Pancreatic Cancer View